Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 3;12(1):193.
doi: 10.3390/plants12010193.

Cannabigerol Activates Cytoskeletal Remodeling via Wnt/PCP in NSC-34: An In Vitro Transcriptional Study

Ivan Anchesi  1 , Federica Betto  1 , Luigi Chiricosta  1 , Agnese Gugliandolo  1 , Federica Pollastro  2 , Stefano Salamone  2 , Emanuela Mazzon  1
Affiliations

Cannabigerol Activates Cytoskeletal Remodeling via Wnt/PCP in NSC-34: An In Vitro Transcriptional Study

Ivan Anchesi et al. Plants (Basel). .

Abstract

Cannabigerol (CBG) is a non-psychoactive phytocannabinoid present in the Cannabis sativa L. plant. In our study, CBG at the concentration of 10 µM was used to treat NSC-34 motor neuron-like cells. The aim of the study was to evaluate the effects of CBG on NSC-34 cells, using next-generation sequencing (NGS) technology. Analysis showed the activation of the WNT/planar cell polarity (PCP) pathway and Ephrin-Eph signaling. The results revealed that CBG increases the expression of genes associated with the onset process of cytoskeletal remodeling and axon guidance.

Keywords: Ephrin-Eph signaling; NSC-34; WNT/planar cell polarity (PCP) signaling; axon guidance; cannabigerol.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Structure of Cannabigerol (1), Cannabidiol (2), and Δ9-tetrahydrocannabinol (3).
Figure 2
Figure 2
Evaluation of possible effects of CBG at concentrations of 1, 5, 10, 15, and 20 µM, and DMSO on NSC-34 cells viability at 24 h, 48 h, and 72 h. No significant difference in cell viability was detected.
Figure 3
Figure 3
The volcano plot shows the behavior of genes in our analysis. Red and blue dots are the genes with p-values lower than 0.05. Additionally, genes represented by red dots have a fold change higher than 0.7 orders of magnitude. The green dots highlight genes with fold changes over the threshold but, along with the grey dots, without p-value significance.
Figure 4
Figure 4
Mechanisms involved in the cytoskeletal remodeling of NSC-34 after CBG treatment. The figure represents pathways involved in the process. A signal influenced by CBG is represented in each oval. Green arrows indicate influence of CB1 activation. Continuous arrows indicate direct associations, while dashed arrows indicate indirect association. A red X indicates that there is no interaction between the receptor and ligand. A red palette indicates genes log2 Fold Change. The results of transcriptomic analysis suggest that CBG induces initial cytoskeletal remodeling of NSC-34 by WNT/planar cell polarity (PCP) signaling, Ephrin-Eph signaling, and the involvement of CB1.
See this image and copyright information in PMC

References

    1. Elsohly M.A., Slade D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci. 2005;78:539–548. doi: 10.1016/j.lfs.2005.09.011. - DOI - PubMed
    1. Rodríguez-Cueto C., Santos-García I., García-Toscano L., Espejo-Porras F., Bellido M., Fernández-Ruiz J., Muñoz E., de Lago E. Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1(G93A) transgenic mice, an experimental model of amyotrophic lateral sclerosis. Biochem. Pharmacol. 2018;157:217–226. doi: 10.1016/j.bcp.2018.07.049. - DOI - PubMed
    1. Granja A.G., Carrillo-Salinas F., Pagani A., Gómez-Cañas M., Negri R., Navarrete C., Mecha M., Mestre L., Fiebich B.L., Cantarero I., et al. A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. J. Neuroimmune Pharmacol. 2012;7:1002–1016. doi: 10.1007/s11481-012-9399-3. - DOI - PubMed
    1. Valdeolivas S., Navarrete C., Cantarero I., Bellido M.L., Muñoz E., Sagredo O. Neuroprotective properties of cannabigerol in Huntington’s disease: Studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics. 2015;12:185–199. doi: 10.1007/s13311-014-0304-z. - DOI - PMC - PubMed
    1. Cascio M.G., Gauson L.A., Stevenson L.A., Ross R.A., Pertwee R.G. Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br. J. Pharmacol. 2010;159:129–141. doi: 10.1111/j.1476-5381.2009.00515.x. - DOI - PMC - PubMed